Published in Biochemistry on May 11, 2010
Isolation of phosphatidylethanolamine as a solitary cofactor for prion formation in the absence of nucleic acids. Proc Natl Acad Sci U S A (2012) 1.97
Cofactor molecules maintain infectious conformation and restrict strain properties in purified prions. Proc Natl Acad Sci U S A (2012) 1.77
Genesis of mammalian prions: from non-infectious amyloid fibrils to a transmissible prion disease. PLoS Pathog (2011) 1.53
Highly efficient protein misfolding cyclic amplification. PLoS Pathog (2011) 1.46
Prion hypothesis: the end of the controversy? Trends Biochem Sci (2010) 1.40
Lower specific infectivity of protease-resistant prion protein generated in cell-free reactions. Proc Natl Acad Sci U S A (2011) 1.26
A new mechanism for transmissible prion diseases. J Neurosci (2012) 1.25
Stabilization of a prion strain of synthetic origin requires multiple serial passages. J Biol Chem (2012) 1.13
Relationship between conformational stability and amplification efficiency of prions. Biochemistry (2011) 1.11
Protein misfolding cyclic amplification of infectious prions. Nat Protoc (2012) 1.10
Dissociation of infectivity from seeding ability in prions with alternate docking mechanism. PLoS Pathog (2011) 1.07
Sulfated dextrans enhance in vitro amplification of bovine spongiform encephalopathy PrP(Sc) and enable ultrasensitive detection of bovine PrP(Sc). PLoS One (2010) 1.05
Seeding specificity and ultrastructural characteristics of infectious recombinant prions. Biochemistry (2011) 1.04
Strain-specific role of RNAs in prion replication. J Virol (2012) 1.04
Isolation of novel synthetic prion strains by amplification in transgenic mice coexpressing wild-type and anchorless prion proteins. J Virol (2012) 1.01
Changes in prion replication environment cause prion strain mutation. FASEB J (2013) 0.99
In situ photodegradation of incorporated polyanion does not alter prion infectivity. PLoS Pathog (2011) 0.97
Acquisition of drug resistance and dependence by prions. PLoS Pathog (2013) 0.96
Assessment of strain-specific PrP(Sc) elongation rates revealed a transformation of PrP(Sc) properties during protein misfolding cyclic amplification. PLoS One (2012) 0.95
Synthesis of high titer infectious prions with cofactor molecules. J Biol Chem (2014) 0.92
In vitro amplification of misfolded prion protein using lysate of cultured cells. PLoS One (2011) 0.91
Critical significance of the region between Helix 1 and 2 for efficient dominant-negative inhibition by conversion-incompetent prion protein. PLoS Pathog (2013) 0.89
Highly infectious prions generated by a single round of microplate-based protein misfolding cyclic amplification. MBio (2013) 0.89
Dissociation of prion protein amyloid seeding from transmission of a spongiform encephalopathy. J Virol (2013) 0.88
Pathology of SSLOW, a transmissible and fatal synthetic prion protein disorder, and comparison with naturally occurring classical transmissible spongiform encephalopathies. Neuropathol Appl Neurobiol (2014) 0.87
Structural requirements for efficient prion protein conversion: cofactors may promote a conversion-competent structure for PrP(C). Prion (2010) 0.86
Introducing a rigid loop structure from deer into mouse prion protein increases its propensity for misfolding in vitro. PLoS One (2013) 0.85
Prion protein misfolding, strains, and neurotoxicity: an update from studies on Mammalian prions. Int J Cell Biol (2013) 0.82
Glycosaminoglycan sulphation affects the seeded misfolding of a mutant prion protein. PLoS One (2010) 0.82
Synthetic scrapie infectivity: interaction between recombinant PrP and scrapie brain-derived RNA. Virulence (2015) 0.81
Early Generation of New PrPSc on Blood Vessels after Brain Microinjection of Scrapie in Mice. MBio (2015) 0.79
Photodegradation illuminates the role of polyanions in prion infectivity. Prion (2011) 0.78
Anti-prion drug mPPIg5 inhibits PrP(C) conversion to PrP(Sc). PLoS One (2013) 0.78
Prion formation, but not clearance, is supported by protein misfolding cyclic amplification. Prion (2014) 0.78
Nucleic acid induced unfolding of recombinant prion protein globular fragment is pH dependent. Protein Sci (2014) 0.77
Prion Strain Differences in Accumulation of PrPSc on Neurons and Glia Are Associated with Similar Expression Profiles of Neuroinflammatory Genes: Comparison of Three Prion Strains. PLoS Pathog (2016) 0.77
A closer look at prion strains: characterization and important implications. Prion (2013) 0.77
Endogenous Brain Lipids Inhibit Prion Amyloid Formation In Vitro. J Virol (2017) 0.76
Phosphatidylethanolamine as a prion cofactor: potential implications for disease pathogenesis. Prion (2012) 0.76
In vitro amplification of scrapie and chronic wasting disease PrP(res) using baculovirus-expressed recombinant PrP as substrate. Prion (2014) 0.75
The prion protein preference of sporadic Creutzfeldt-Jakob disease subtypes. J Biol Chem (2012) 0.75
Heparan Sulfate and Heparin Promote Faithful Prion Replication in Vitro by Binding to Normal and Abnormal Prion Proteins in Protein Misfolding Cyclic Amplification. J Biol Chem (2016) 0.75
Nanomedicine for prion disease treatment: new insights into the role of dendrimers. Prion (2013) 0.75
Region-specific protein misfolding cyclic amplification reproduces brain tropism of prion strains. J Biol Chem (2017) 0.75
An in vitro approach to identify the key amino acids in the low susceptibility of rabbit PrP to misfolding. J Virol (2017) 0.75
Types and Strains: Their Essential Role in Understanding Protein Aggregation in Neurodegenerative Diseases. Front Aging Neurosci (2017) 0.75
In vitro generation of infectious scrapie prions. Cell (2005) 6.86
Generating a prion with bacterially expressed recombinant prion protein. Science (2010) 6.26
Formation of native prions from minimal components in vitro. Proc Natl Acad Sci U S A (2007) 5.94
Prion propagation in mice expressing human and chimeric PrP transgenes implicates the interaction of cellular PrP with another protein. Cell (1995) 5.16
Shattuck lecture--neurodegenerative diseases and prions. N Engl J Med (2001) 4.75
RNA molecules stimulate prion protein conversion. Nature (2003) 4.06
Evidence for protein X binding to a discontinuous epitope on the cellular prion protein during scrapie prion propagation. Proc Natl Acad Sci U S A (1997) 3.78
Cholesterol depletion and modification of COOH-terminal targeting sequence of the prion protein inhibit formation of the scrapie isoform. J Cell Biol (1995) 3.66
Protease-resistant prion protein amplification reconstituted with partially purified substrates and synthetic polyanions. J Biol Chem (2005) 2.29
The 37-kDa/67-kDa laminin receptor acts as the cell-surface receptor for the cellular prion protein. EMBO J (2001) 2.16
Conversion of raft associated prion protein to the protease-resistant state requires insertion of PrP-res (PrP(Sc)) into contiguous membranes. EMBO J (2002) 2.16
Crossing the species barrier by PrP(Sc) replication in vitro generates unique infectious prions. Cell (2008) 2.09
Chronic lymphocytic inflammation specifies the organ tropism of prions. Science (2005) 2.07
Scrapie strain variation and mutation. Br Med Bull (1993) 2.06
Sulfated glycans and elevated temperature stimulate PrP(Sc)-dependent cell-free formation of protease-resistant prion protein. EMBO J (2001) 1.95
Ectopic expression of prion protein (PrP) in T lymphocytes or hepatocytes of PrP knockout mice is insufficient to sustain prion replication. Proc Natl Acad Sci U S A (1999) 1.81
Chaperone-supervised conversion of prion protein to its protease-resistant form. Proc Natl Acad Sci U S A (1997) 1.79
Selective incorporation of polyanionic molecules into hamster prions. J Biol Chem (2007) 1.71
Dominant-negative inhibition of prion replication in transgenic mice. Proc Natl Acad Sci U S A (2002) 1.65
Lipid interaction converts prion protein to a PrPSc-like proteinase K-resistant conformation under physiological conditions. Biochemistry (2007) 1.62
The stoichiometry of host PrPC glycoforms modulates the efficiency of PrPSc formation in vitro. Biochemistry (2006) 1.56
Dominant-negative inhibition of prion formation diminished by deletion mutagenesis of the prion protein. J Virol (2000) 1.52
Properties of scrapie prion protein liposomes. J Biol Chem (1988) 1.47
Structural changes of the prion protein in lipid membranes leading to aggregation and fibrillization. Biochemistry (2003) 1.45
Cellular heparan sulfate participates in the metabolism of prions. J Biol Chem (2003) 1.34
Prion protein glycosylation is not required for strain-specific neurotropism. J Virol (2009) 1.31
Sphingolipid depletion increases formation of the scrapie prion protein in neuroblastoma cells infected with prions. J Biol Chem (1999) 1.29
Trans-dominant inhibition of prion propagation in vitro is not mediated by an accessory cofactor. PLoS Pathog (2009) 1.21
Generation of genuine prion infectivity by serial PMCA. Vet Microbiol (2007) 1.19
Reconstitution of prion infectivity from solubilized protease-resistant PrP and nonprotein components of prion rods. J Biol Chem (2001) 1.15
Prion rods contain small amounts of two host sphingolipids as revealed by thin-layer chromatography and mass spectrometry. Biol Chem (1998) 1.00
Prion strains. Curr Top Microbiol Immunol (1996) 0.95
Reduction of prion infectivity and levels of scrapie prion protein by lithium aluminum hydride: implications for RNA in prion diseases. J Neuropathol Exp Neurol (2009) 0.90
Formation of native prions from minimal components in vitro. Proc Natl Acad Sci U S A (2007) 5.94
Osteocyte control of bone formation via sclerostin, a novel BMP antagonist. EMBO J (2003) 4.32
RNA molecules stimulate prion protein conversion. Nature (2003) 4.06
Structural studies of the scrapie prion protein by electron crystallography. Proc Natl Acad Sci U S A (2002) 2.91
Protease-resistant prion protein amplification reconstituted with partially purified substrates and synthetic polyanions. J Biol Chem (2005) 2.29
Isolation of phosphatidylethanolamine as a solitary cofactor for prion formation in the absence of nucleic acids. Proc Natl Acad Sci U S A (2012) 1.97
Sclerostin inhibition of Wnt-3a-induced C3H10T1/2 cell differentiation is indirect and mediated by bone morphogenetic proteins. J Biol Chem (2004) 1.91
Cofactor molecules maintain infectious conformation and restrict strain properties in purified prions. Proc Natl Acad Sci U S A (2012) 1.77
Selective incorporation of polyanionic molecules into hamster prions. J Biol Chem (2007) 1.71
Sclerostin promotes the apoptosis of human osteoblastic cells: a novel regulation of bone formation. Bone (2004) 1.71
Accelerated accumulation of misfolded prion protein and spongiform degeneration in a Drosophila model of Gerstmann-Sträussler-Scheinker syndrome. J Neurosci (2006) 1.69
The stoichiometry of host PrPC glycoforms modulates the efficiency of PrPSc formation in vitro. Biochemistry (2006) 1.56
Removal of exogenous (spiked) and endogenous prion infectivity from red cells with a new prototype of leukoreduction filter. Transfusion (2005) 1.51
Inactivation of prions by acidic sodium dodecyl sulfate. J Virol (2006) 1.43
Efficient in vitro amplification of chronic wasting disease PrPRES. J Virol (2007) 1.42
Prion protein glycosylation is not required for strain-specific neurotropism. J Virol (2009) 1.31
Noggin and sclerostin bone morphogenetic protein antagonists form a mutually inhibitory complex. J Biol Chem (2004) 1.26
Trans-dominant inhibition of prion propagation in vitro is not mediated by an accessory cofactor. PLoS Pathog (2009) 1.21
Passage of chronic wasting disease prion into transgenic mice expressing Rocky Mountain elk (Cervus elaphus nelsoni) PrPC. J Gen Virol (2006) 1.20
Small, highly structured RNAs participate in the conversion of human recombinant PrP(Sen) to PrP(Res) in vitro. J Mol Biol (2003) 1.17
Copper (II) ions potently inhibit purified PrPres amplification. J Neurochem (2006) 1.16
In vitro amplification of protease-resistant prion protein requires free sulfhydryl groups. Biochemistry (2003) 1.15
Short hairpin RNA-mediated inhibition of matrix metalloproteinase-1 in MDA-231 cells: effects on matrix destruction and tumor growth. Cancer Res (2005) 1.13
Dissociation of infectivity from seeding ability in prions with alternate docking mechanism. PLoS Pathog (2011) 1.07
Immunomodulation targeting abnormal protein conformation reduces pathology in a mouse model of Alzheimer's disease. PLoS One (2010) 1.07
Unique regulation of SOST, the sclerosteosis gene, by BMPs and steroid hormones in human osteoblasts. Bone (2004) 1.06
Cofactor molecules induce structural transformation during infectious prion formation. Structure (2013) 1.05
The effects of prion protein proteolysis and disaggregation on the strain properties of hamster scrapie. J Gen Virol (2008) 1.05
Seeding specificity and ultrastructural characteristics of infectious recombinant prions. Biochemistry (2011) 1.04
Protein folding activity of ribosomal RNA is a selective target of two unrelated antiprion drugs. PLoS One (2008) 0.98
In situ photodegradation of incorporated polyanion does not alter prion infectivity. PLoS Pathog (2011) 0.97
Immunodetection of glycophosphatidylinositol-anchored proteins following treatment with phospholipase C. Anal Biochem (2007) 0.97
RNAi or overexpression: alternative therapies for Spinocerebellar Ataxia Type 1. Neurobiol Dis (2013) 0.94
Sialic acid deposition impairs the utility of AAV9, but not peptide-modified AAVs for brain gene therapy in a mouse model of lysosomal storage disease. Mol Ther (2012) 0.93
The N-terminal, polybasic region of PrP(C) dictates the efficiency of prion propagation by binding to PrP(Sc). J Neurosci (2012) 0.93
Ionic strength and transition metals control PrPSc protease resistance and conversion-inducing activity. J Biol Chem (2004) 0.91
Fragile X screening by quantification of FMRP in dried blood spots by a Luminex immunoassay. J Mol Diagn (2013) 0.90
Requirements for mutant and wild-type prion protein misfolding in vitro. Biochemistry (2015) 0.85
Prion nucleation site unmasked by transient interaction with phospholipid cofactor. Biochemistry (2014) 0.85
Reiterating the epitope specificity of prion-specific mAb 3F4. J Biol Chem (2010) 0.84
Elucidating the role of cofactors in mammalian prion propagation. Prion (2014) 0.82
Post-transcriptional suppression of pathogenic prion protein expression in Drosophila neurons. J Neurochem (2003) 0.82
Superparamagnetic nanoparticle capture of prions for amplification. J Virol (2011) 0.82
In vitro prion protein conversion in detergent-solubilized membranes. Biochemistry (2004) 0.81
Photodegradation illuminates the role of polyanions in prion infectivity. Prion (2011) 0.78
Non-reducing alkaline solubilization and rapid on-column refolding of recombinant prion protein. Prep Biochem Biotechnol (2012) 0.76
What makes a good prion? Conference on Prion Biology. EMBO Rep (2006) 0.75
On the horizon: a blood test for prions. Trends Microbiol (2006) 0.75